Scientists have developed an experimental mRNA vaccine, Intismeran, which individually trains patients' immune systems to fight melanoma, reducing the risk of recurrence and prolonging the remission period in combination with the immunotherapy Keytruda. (translated)
За мен новината е историческа и намирам, че не е достатъчно отразена. На 19 август 2026 г. Moderna и Merck (MSD) обявиха резултатите от мащабно клинично изпитване във фаза 3: Персонализираната mRNA ваксина срещу меланом (intismeran / mRNA-4157) в комбинация с Keytruda значително намалява риска от връщане и разпространение на рака. Това е първата mRNA противоракова ваксина, която успешно преминава късна фаза на клинични изпитвания. В проучването участваха над 1100 пациенти с висок риск за меланом (стадий IIB–IV), при които туморът е бил напълно отстранен хирургично. Комбинацията ваксина + Keytruda значително удължава времето без рецидив (recurrence-free survival) и намалява риска от поява на далечни метастази в сравнение само с Keytruda. Ваксината е напълно персонализирана - създава се специално за всеки пациент въз основа на уникалните мутации на неговия тумор. Използва се същата mRNA технология, която познаваме от ваксините срещу COVID-19. Това не е просто пореден „пробив в лабораторията“. Това е реална стъпка към нова ера в онкологията. Резултатите вече се наричат „landmark“ (исторически) от водещи онколози. Компаниите планират да подадат документи за одобрение от регулаторите в близките месеци. Ако всичко върви добре, хиляди пациенти могат да се възползват още през 2027 г. Понякога истински революции идват тихо, но променят живота на хиляди хора. #mRNAvaccine #oncology #cancerresearch
Moderna and Merck announced successful results from the Phase III study of their personalized mRNA vaccine for melanoma in combination with the immunotherapy Keytruda, which could mean a revolution in cancer treatment by tailoring therapy to the genetic profile of the tumor, although detailed data from studies and regulatory approval are still lacking. (translated)
Moderna and Merck have announced an important discovery in cancer vaccine research, demonstrating the effectiveness of an experimental mRNA vaccine called Intismeran in combination with the immunotherapy Keytruda for the treatment of melanoma, the most aggressive type of skin cancer. (translated)
Moderna is profiting from the successful results of the clinical trial of its mRNA vaccine Intismeran against melanoma, which, in combination with the immunotherapy Keytruda, has led to a significant increase in the company's stock prices and hope for future approval of the treatment. (translated)
Merck and Moderna announced positive results for a messenger RNA therapeutic vaccine against advanced melanoma, showing a significant improvement in recurrence-free survival in combination with the immunotherapy Keytruda, marking an important advance in personalized treatments for this deadly skin cancer. (translated)
Moderna has published positive results from a clinical study on a novel mRNA skin cancer vaccine, which in combination with the checkpoint inhibitor Keytruda could significantly reduce the risk of relapse and the spread of melanomas in high-risk patients, opening up the prospect of swift approval and availability of the vaccine next year. (translated)
The laboratories Moderna and Merck announced promising results for their therapeutic vaccine against melanoma, which, in combination with the immunotherapy Keytruda, showed a significant improvement in relapse-free survival in patients with advanced skin cancer. (translated)
Research on the personalized vaccine intismeran, administered in combination with the immunotherapy Keytruda, showed an extension of the relapse-free period of melanoma and a reduction in the risk of metastasis, which has raised hopes for a new era of oncology therapies and positive reactions on the stock market. (translated)
Shares of Moderna more than doubled after the announcement of positive results from clinical trials of a personalized cancer therapy in combination with the drug Keytruda, which triggered a significant increase in investor interest. (translated)
A successful clinical study of the personalized mRNA skin cancer vaccine Intismeran by Moderna in combination with the immunotherapy Keytruda has led to an over 150 percent increase in Moderna's stock price and a record high for Merck & Co. stocks. (translated)
Moderna and Merck have revealed promising results in the phase 3 clinical trials of their personalized vaccine against advanced melanoma, which, when combined with Keytruda, has shown a significant improvement in relapse-free survival, marking a milestone in the use of messenger RNA-based cancer therapy. (translated)
Moderna and Merck have announced promising preliminary results from the phase 3 study comparing a personalized mRNA therapy, autogene intismeran, combined with the immunotherapy KEYTRUDA, showing a significant reduction in the risk of recurrence and metastasis in patients operated on for advanced melanoma, which caused Moderna's stock to soar by 96% in pre-market trading. (translated)
The personalized mRNA vaccine Intismeran from Moderna showed promising results in a clinical trial, reducing the risk of recurrence and spread of melanoma when administered alongside Merck's Keytruda immunotherapy, and interim data indicate successful achievements in the primary goals of the study. (translated)
Der Preis des kostspieligen Krebsmedikaments Keytruda sorgt für rechtliche Kontroversen in Österreich, da mehrere Landesverwaltungsgerichte unterschiedlich entschieden haben, ob dieser Preis veröffentlicht werden muss, was nun den Verfassungsgerichtshof (VfGH) beschäftigt. #Keytruda #Medikamentenpreise #VfGH
Le coût élevé du traitement anticancéreux Keytruda, s'élevant à 70.000 euros par patient et représentant la plus grande dépense remboursée par la Sécurité sociale en France, suscite des débats sur l'accessibilité et la nécessité d'investissements accrus dans l'innovation pharmaceutique, malgré les plaintes des laboratoires concernant les coupes budgétaires. #MédicamentsInnovants #Sécu #SantéPublique
25-year-old Abdul Karim is urgently fighting relapsed Hodgkin lymphoma in Bulgaria. Doctors insist he must start Keytruda treatment next week. You can now support him through DMS: 📱 SMS with text DMS ABDUL KARIM to 17 777 or donate here: https://t.co/jtgEsRPvfw #HodgkinLymphoma #Keytruda #SupportAbdul #BG
25-year-old Abdul Karim is fighting relapsed Hodgkin lymphoma in Bulgaria. Doctors insist he must start Keytruda treatment next week. €5273 are urgently needed for the first cycle of chemotherapy. Full treatment is €22 000 Please help or share: https://t.co/eLZl4RJGRp #HodgkinLymphoma #Keytruda #CancerTreatment #BG
Der Artikel berichtet über die Bemühungen von DER STANDARD und profil, den geheimen Preis von Keytruda, dem teuersten Krebsmedikament der Welt, durch Informationsfreiheitsanträge vor neun Landesverwaltungsgerichten in Österreich zu ermitteln, während der Pharmakonzern MSD und andere Parteien juristisch gegen diese Transparenz vorgehen. #Keytruda #Gesundheitssystem #Informationsfreiheit
Health Minister Mike Nesbitt has announced that pembrolizumab (Keytruda), an injectable immunotherapy drug for multiple cancers, is currently available in three of Northern Ireland's five health trusts, with plans to expand access to all trusts soon, offering a quicker and less intrusive treatment option compared to traditional intravenous administration. #CancerTreatment #Immunotherapy #HealthCare #GB #NI #WA
